PMID- 11527924
OWN - NLM
STAT- MEDLINE
DCOM- 20010927
LR  - 20071114
IS  - 0146-0404 (Print)
IS  - 0146-0404 (Linking)
VI  - 42
IP  - 10
DP  - 2001 Sep
TI  - Association of HLA class I and class II antigen expression and mortality in uveal 
      melanoma.
PG  - 2153-6
AB  - PURPOSE: Malignant transformation of cells is frequently associated with 
      abnormalities in human leukocyte antigen (HLA) expression. These abnormalities 
      may play a role in the clinical course of the disease, because HLA antigens 
      mediate interactions of tumor cells with T cells and NK cells. Uveal melanoma is 
      a highly malignant tumor of the eye and is characterized by a hematogenic spread 
      to the liver. Little is known about the role of HLA expression in progression of 
      this malignant disease. METHODS: In the present study HLA class I antigen, 
      beta(2)-microglobulin (beta(2)-m), and HLA class II antigen expression was 
      analyzed in primary uveal melanoma lesions by immunoperoxidase staining with 
      monoclonal antibodies of 65 archival clinical samples. The results were 
      correlated with the clinical course of the disease. RESULTS: HLA class I antigen 
      expression and beta(2)-m expression were downregulated in 40 and 35 lesions, 
      respectively. HLA class II antigens were expressed in 30 lesions. Patients with 
      high HLA class I, including beta(2)-m, and HLA class II antigen expression in 
      their primary melanoma lesions had a significantly decreased survival (P = 0.009, 
      P < 0.001, and P = 0.006, respectively). CONCLUSIONS: The findings argue against 
      a major role of cytotoxic T-lymphocyte (CTL)-mediated control of tumor growth in 
      the clinical course of uveal melanoma and are compatible with a potential role of 
      NK-cell-mediated control of hematogenic metastatic spread.
FAU - Ericsson, C
AU  - Ericsson C
AD  - St. Erik's Eye Hospital, Stockholm, Sweden.
FAU - Seregard, S
AU  - Seregard S
FAU - Bartolazzi, A
AU  - Bartolazzi A
FAU - Levitskaya, E
AU  - Levitskaya E
FAU - Ferrone, S
AU  - Ferrone S
FAU - Kiessling, R
AU  - Kiessling R
FAU - Larsson, O
AU  - Larsson O
LA  - eng
GR  - CAA67108/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Invest Ophthalmol Vis Sci
JT  - Investigative ophthalmology & visual science
JID - 7703701
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (Histocompatibility Antigens Class II)
RN  - 0 (beta 2-Microglobulin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antibodies, Monoclonal
MH  - Down-Regulation
MH  - Female
MH  - Histocompatibility Antigens Class I/*metabolism
MH  - Histocompatibility Antigens Class II/*metabolism
MH  - Humans
MH  - Immunoenzyme Techniques
MH  - Killer Cells, Natural/physiology
MH  - Male
MH  - Melanoma/metabolism/*mortality
MH  - Middle Aged
MH  - T-Lymphocytes, Cytotoxic/physiology
MH  - Uveal Neoplasms/metabolism/*mortality
MH  - beta 2-Microglobulin/metabolism
EDAT- 2001/08/31 10:00
MHDA- 2001/09/28 10:01
CRDT- 2001/08/31 10:00
PHST- 2001/08/31 10:00 [pubmed]
PHST- 2001/09/28 10:01 [medline]
PHST- 2001/08/31 10:00 [entrez]
PST - ppublish
SO  - Invest Ophthalmol Vis Sci. 2001 Sep;42(10):2153-6.